Theurillat JP et al. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014; 346(6205):85-59. PMID: 25278611.
Janouskova H et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017; 23(9):1046-1054. PMID: 28805821.
Nabais Sá MJ et al. De Novo Variants in SPOP Cause Two Clinically Distinct Neurodevelopmental Disorders. Am J Hum Genet. 2020;106(3):405-411. PMID: 32109420.
SPOP LoF